Unleashing Potential in a High-profile Drug Target Superfamily
We see the unseen: additional therapeutic potential in nuclear receptors, a drug target superfamily, and are exploring this unknown territory. Nuclear receptors are well-known in the scientific community. Oral drugs based on the nuclear receptors have successfully treated breast and prostate cancer, type 2 diabetes, and inflammatory disease. Recent research shows they hold promise for many other indications, including non-alcoholic steatohepatitis, or NASH. Nuclear receptors are unique among transcription factors since they have well-defined pockets that allow regulation by highly potent and selective small molecule ligands.
We combine imagination, scientific rigor, and broad-based technologies in our focused research strategy. To begin, we developed high-throughput assays for several unexplored or orphan nuclear receptors and screened these against diverse compound libraries to identify selective chemical probes. Next, by implementing orthogonal assays, we confirmed the direct binding of these chemical probes to the receptor ligand-binding domain. In several cases, we identified both agonist and antagonist probe compounds that were used to support target validation.
Lead compounds were optimized by iterative medicinal chemistry to improve drug-like properties. Subsequently, by tapping into the scientific literature, publicly available databases, and our internal exploratory pharmacology, our scientific team developed therapeutic hypotheses and identified potential addressable patient populations. This strategy yielded three significant Orphagen pipeline programs.
Partnerships and Collaborations
Orphagen believes strongly in partnerships and collaborations to accelerate our path to discovery, clinical development and commercialization. We have attracted significant partners and continue to be open to a wide range of collaborators. As we approach a pivotal company milestone of moving into clinical development with OR-449, we will continue to evaluate collaboration and business development opportunities for both this lead candidate and other programs.
Our legacy of successful partnerships began in 2008. Orphagen achieved a major strategic partnership with the Pharmaceutical Division of Japan Tobacco (JT) for further development of small molecule antagonists to the orphan nuclear receptor RORγ for autoimmune diseases such as psoriasis. The partnership was the first of many competitive development programs for oral RORγ antagonists that swept the industry including major pharmaceutical companies such as Merck, Pfizer, Amgen, J&J, AbbVie, GSK, and Takeda. Orphagen has entered into smaller research collaborations with several other pharmaceutical companies based on its internally developed technology.
Looking to the future, we embrace active discussions with potential partners looking to collaborate.
Recent publications on OR-449